Use of site-specified tritium labelling to confirm the formation of 17-oxosparteine as a minor urinary metabolite of sparteine in man.
1. The synthesis of [17,17-3H2]-sparteine and its oral administration has enabled the specific identification of 17-oxosparteine as a minor urinary metabolite (approximately 1% dose) in two healthy male volunteers.
Ritchie
J C
JC
Imperial College School of Medicine at St Mary's, London, UK.
Mitchell
S C
SC
Smith
R L
RL
Zhang
A Q
AQ
D000284:Administration, Oral; D000328:Adult; D001665:Binding Sites; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D013034:Sparteine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics* / Q000652:urine; D014316:Tritium / Q000008:administration & dosage / Q000493:pharmacokinetics*
D014316:Tritium; D013034:Sparteine; C035707:17-oxosparteine